These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 35738030)
1. Does cannabis testing in the military drive synthetic cannabinoid use? Self-reported use motivations among justice-involved veterans. Santangelo O; Baldwin JM; Stogner J Int J Drug Policy; 2022 Aug; 106():103756. PubMed ID: 35738030 [TBL] [Abstract][Full Text] [Related]
2. Clinical withdrawal symptom profile of synthetic cannabinoid receptor agonists and comparison of effects with high potency cannabis. Craft S; Ferris JA; Barratt MJ; Maier LJ; Lynskey MT; Winstock AR; Freeman TP Psychopharmacology (Berl); 2022 May; 239(5):1349-1357. PubMed ID: 34533608 [TBL] [Abstract][Full Text] [Related]
3. The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients. Jackson MA; Brown AL; Johnston J; Clancy R; McGregor I; Bruno R; Lintzeris N; Montebello M; Luksza J; Bowman J; Phung N; Allsop D; Dunlop AJ J Cannabis Res; 2021 Jul; 3(1):33. PubMed ID: 34311790 [TBL] [Abstract][Full Text] [Related]
4. Synthetic cannabinoid use among a sample of individuals enrolled in community-based recovery programs: Are synthetic cannabinoids actually preferred to other drugs? Smith KE; Staton M Subst Abus; 2019; 40(2):160-169. PubMed ID: 30457960 [No Abstract] [Full Text] [Related]
5. 'Spice' Use Motivations, Experiences, and Repercussions among Veterans of the United States Armed Forces. Stogner J; Baldwin JM; Wiercioch A Subst Use Misuse; 2024; 59(8):1182-1189. PubMed ID: 38548662 [TBL] [Abstract][Full Text] [Related]
6. Brief report: Synthetic cannabinoid use among military personnel. Stogner J; Santangelo O; Baldwin JM Am J Addict; 2024 Jan; 33(1):96-99. PubMed ID: 37717217 [TBL] [Abstract][Full Text] [Related]
7. Activity-based detection of synthetic cannabinoid receptor agonists in plant materials. Timmerman A; Balcaen M; Coopman V; Degreef M; Pottie E; Stove CP Harm Reduct J; 2024 Jul; 21(1):127. PubMed ID: 38951904 [TBL] [Abstract][Full Text] [Related]
8. Characterizing Trends in Synthetic Cannabinoid Receptor Agonist Use from Patient Clinical Evaluations during Medical Toxicology Consultation. Tebo C; Mazer-Amirshahi M; Wax P; Campleman S; Boyer E; Brent J; Sheth A; Daniuaityte R; Carlson R J Psychoactive Drugs; 2021; 53(3):207-214. PubMed ID: 33225872 [TBL] [Abstract][Full Text] [Related]
9. Clinical Effects of Synthetic Cannabinoid Receptor Agonists Compared with Marijuana in Emergency Department Patients with Acute Drug Overdose. Zaurova M; Hoffman RS; Vlahov D; Manini AF J Med Toxicol; 2016 Dec; 12(4):335-340. PubMed ID: 27255136 [TBL] [Abstract][Full Text] [Related]
12. Suspected synthetic cannabinoid receptor agonist intoxication: Does analysis of samples reflect the presence of suspected agents? Tebo C; Mazer-Amirshahi M; DeGeorge L; Gelfand B; Leak C; Tolliver S; Sauter D Am J Emerg Med; 2019 Oct; 37(10):1846-1849. PubMed ID: 30595429 [TBL] [Abstract][Full Text] [Related]
13. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. van Amsterdam J; Brunt T; van den Brink W J Psychopharmacol; 2015 Mar; 29(3):254-63. PubMed ID: 25586398 [TBL] [Abstract][Full Text] [Related]
15. Cannabis and Cannabinoids for Pain and Posttraumatic Stress Disorder in Military Personnel and Veterans. Wolfgang AS; Hoge CW JAMA Psychiatry; 2023 Sep; 80(9):869-870. PubMed ID: 37436761 [TBL] [Abstract][Full Text] [Related]
16. Clinical effects of cannabis compared to synthetic cannabinoid receptor agonists (SCRAs): a retrospective cohort study of presentations with acute toxicity to European hospitals between 2013 and 2020. Waters ML; Dargan PI; Yates C; Dines AM; Eyer F; Giraudon I; Heyerdahl F; Hovda KE; Liechti ME; Miró Ò; Vallersnes OM; Anseeuw K; Badaras R; Bitel M; Bonnici J; Brvar M; Caganova B; Calýskan F; Ceschi A; Chamoun K; Daveloose L; Galicia M; Gartner B; Gorozia K; Grenc D; Gresnigt FMJ; Hondebrink L; Jürgens G; Konstari J; Kutubidze S; Laubner G; Liakoni E; Liguts V; Lyphout C; McKenna R; Mégarbane B; Moughty A; Nitescu GV; Noseda R; O'Connor N; Paasma R; Ortega Perez J; Perminas M; Persett PS; Põld K; Puchon E; Puiguriguer J; Radenkova-Saeva J; Rulisek J; Samer C; Schmid Y; Scholz I; Stašinskis R; Surkus J; Van den Hengel-Koot I; Vigorita F; Vogt S; Waldman W; Waring WS; Zacharov S; Zellner T; Wood DM Clin Toxicol (Phila); 2024 Jun; 62(6):378-384. PubMed ID: 38934347 [TBL] [Abstract][Full Text] [Related]
17. Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists. Patel M; Manning JJ; Finlay DB; Javitch JA; Banister SD; Grimsey NL; Glass M Biochem Pharmacol; 2020 May; 175():113871. PubMed ID: 32088263 [TBL] [Abstract][Full Text] [Related]
18. Adding more "spice" to the pot: A review of the chemistry and pharmacology of newly emerging heterocyclic synthetic cannabinoid receptor agonists. Alam RM; Keating JJ Drug Test Anal; 2020 Mar; 12(3):297-315. PubMed ID: 31854124 [TBL] [Abstract][Full Text] [Related]
19. 'Synthetic cannabis': A dangerous misnomer. Darke S; Banister S; Farrell M; Duflou J; Lappin J Int J Drug Policy; 2021 Dec; 98():103396. PubMed ID: 34343944 [TBL] [Abstract][Full Text] [Related]